23:02 , Jul 10, 2019 |  BC Extra  |  Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

As it gears up to enter the clinic next quarter, neurodegeneration company Yumanity hired Richard Peters as CEO to succeed Tony Coles, aiming to leverage Peters’ experience managing neurology trials into at least three clinical...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
04:46 , Jun 21, 2018 |  BC Extra  |  Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
19:08 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Kezar files to raise $80.5M in IPO on NASDAQ

Kezar Life Sciences Inc. (South San Francisco, Calif.) filed May 24 to raise $80.5 million in an IPO on NASDAQ underwritten by Jefferies, Cowen, Wells Fargo and William Blair. Kezar is developing immunoproteasome-targeted therapeutics to...
21:08 , May 25, 2018 |  BC Extra  |  Financial News

Immunoproteasome company Kezar files for $80.5M IPO

Kezar Life Sciences Inc. (South San Francisco, Calif.) filed Thursday to raise $80.5 million in an IPO on NASDAQ underwritten by Jefferies, Cowen, Wells Fargo and William Blair. Kezar is developing immunoproteasome-targeted therapeutics to selectively...
20:11 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Amgen's Kyprolis meets OS endpoint in Phase III ASPIRE trial for MM

Amgen Inc. (NASDAQ:AMGN) reported additional data from the Phase III ASPIRE trial in 792 patients with relapsed or refractory multiple myeloma (MM) following treatment with 1-3 prior regimens showing that Kyprolis carfilzomib (PR-171, ONO-7057) plus...
22:05 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Once-weekly dosing of Kyprolis improves PFS vs. twice-weekly option

Amgen Inc. (NASDAQ:AMGN) reported interim data from the Phase III ARROW trial in 478 patients with relapsed and refractory multiple myeloma (MM) showing that 70 mg/m 2 Kyprolis carfilzomib (ONO-7057, PR-171) administered once weekly led...
21:42 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Regeneron to discontinue nesvacumab/Eylea combo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it will discontinue development of a fixed combination therapy comprising nesvacumab (REGN910) plus Eylea aflibercept to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) after the combination...
22:10 , Nov 27, 2017 |  BC Extra  |  Clinical News

Regeneron discontinues Eylea/nesvacumab combo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it will discontinue development of a fixed combination therapy comprising nesvacumab (REGN910) plus Eylea aflibercept to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) after the combination...